Table 3 Active clinical trials investigating future immunotherapies in mRCC
From: New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy
Trial | Phase | Estimated completion | Disease setting | Standard treatment | Experimental treatment |
|---|---|---|---|---|---|
NCT01582672 | III | April 2017 | Advanced renal cell carcinoma | Sunitinib | Sunitinib + AGS-003 |
NCT02459067 | II/III | December 2017 | Refractory: Malignant Melanoma NSCLC Renal cell cancer | None | ImmuniCell® |
NCT02917772 | II | April 2018 | Advanced renal cell carcinoma | None | Nivolumab + ipilimumab |
NCT02718066 | Ib/II | September 2017 | Refractory: Malignant Melanoma NSCLC Renal cell cancer | None | Nivolumab + HBI-8000 |
NCT02853331 | III | December 2019 | Metastatic ccRCC | Sunitinib | Pembrolizumab + axitinib |
NCT02684006 | III | June 2018 | Metastatic ccRCC | Sunitinib | Avelumab + axitinib |
NCT02231749 | III | June 2019 | Advanced renal cell carcinoma | Sunitinib | Nivolumab + ipilimumab |
NCT02420821 | III | July 2020 | Advanced renal cell carcinoma | Sunitinib | Bevacizumab + atezolizumab |
NCT02811861 | III | October 2019 | Metastatic ccRCC | Sunitinib | Lenvatinib + everolimus OR Lenvatinib + pembrolizumab |